Stocks to Buy based on the Best Stock Market Research
SNOA (MC $23 M)(Cash $13 M) Shares Out 4.3 M / Lots of Marketed Products some of them are in early launch phase plus additional Product launches expected within 6 months / Revenue close to hit $16 million/Profitability expected in 2018 . This undiscovered and revenue generating company is one if not the cheapest pharma you can get at this time .This Stock looking fantastic on all fronts it has a terrible low valuation of $23 Million is well financed with around $13 million and has a ultra low O/S of only 4.3 million .
This low float stock has the potential to hit $50 per share (~ $215 Million) within 12-18 months and even then the valuation would be still low . GL
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million
Cash: $12.6 Million
Shares Out : 4.3 Million
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
•Mondoxyne for severe acne –launched late 2015
•Ceramax for skin repair in atopic dermatitis–launched in April 2016
•SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017
•Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
Regulatory Approvals and Clearances
To date, we have obtained 17 clearances from the U.S. Food and Drug Administration, or FDA, that permit us to sell our products as medical devices for Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States.
Outside the United Sates, we sell products for dermatological and advanced tissue care with a European Conformity marking (known as Conformité Européenne or CE) covering 25 of our products, and various approvals in Central America, China, Southeast Asia, and the Middle East.
Replies to This Discussion
New Fact Sheet ....
Ø Pure play dermatology-focused company, building multi-technology platform
Ø Products based on core Microcyn®Technology and in-licensing
Ø Addressable dermatitis market of 16.5 million prescriptions or ~$1.5+ billion, with good pricing flexibility and profitability
Ø Double-digit US product revenue growth providing affordable, unique & effective products –launching one per
Great News out today ...
Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products